168 related articles for article (PubMed ID: 23215767)
41. The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins.
Stein MR
Postgrad Med; 2010 Sep; 122(5):176-84. PubMed ID: 20861601
[TBL] [Abstract][Full Text] [Related]
42. A case of lichenoid drug eruption associated with subcutaneous immunoglobulin therapy.
Beccastrini E; Emmi G; Caproni M; Antiga E; Francalanci S; Lorenzoni A; Emmi L
Clin Immunol; 2011 May; 139(2):228-30. PubMed ID: 21402497
[No Abstract] [Full Text] [Related]
43. Another subcutaneous immune globulin (Cuvitru) for primary immunodeficiency.
Med Lett Drugs Ther; 2017 May; 59(1521):e88-e89. PubMed ID: 28520701
[No Abstract] [Full Text] [Related]
44. Intravenous immunoglobulin: a review.
Eibl MM; Wedgwood RJ
Immunodefic Rev; 1989; 1 Suppl():1-42. PubMed ID: 2698646
[TBL] [Abstract][Full Text] [Related]
45. Hizentra for the treatment of primary immunodeficiency.
Wasserman RL
Expert Rev Clin Immunol; 2014 Oct; 10(10):1293-307. PubMed ID: 25182658
[TBL] [Abstract][Full Text] [Related]
46. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.
Jolles S; Sleasman JW
Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653
[TBL] [Abstract][Full Text] [Related]
47. In-line warming reduces in-line pressure of subcutaneous infusion of concentrated immunoglobulins.
Leidenmühler P; Höfinghoff J; Haider N; Brachtl G; Weiller M; Bilic I; Gangadharan B
Drug Deliv Transl Res; 2023 Sep; 13(9):2367-2377. PubMed ID: 36920736
[TBL] [Abstract][Full Text] [Related]
48. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency.
Fasth A; Nyström J
Acta Paediatr; 2007 Oct; 96(10):1474-8. PubMed ID: 17850391
[TBL] [Abstract][Full Text] [Related]
49. The pocketbook: Pharmacoeconomic issues related to intravenous immunoglobulin therapy.
Mahadevia PJ
Pharmacotherapy; 2005 Nov; 25(11 Pt 2):94S-100S. PubMed ID: 16229680
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of a new intravenous immunoglobulin preparation in primary immunodeficient patients.
Ochs HD; Lee ML; Fischer SH; Kingdon HS; Wedgwood RJ
Clin Ther; 1987; 9(5):512-22. PubMed ID: 3117369
[TBL] [Abstract][Full Text] [Related]
51. Subcutaneous immunoglobulin replacement in primary immunodeficiencies.
Berger M
Clin Immunol; 2004 Jul; 112(1):1-7. PubMed ID: 15207776
[TBL] [Abstract][Full Text] [Related]
52. Subcutaneous immunoglobulin replacement therapy: the European experience.
Chapel H; Gardulf A
Curr Opin Allergy Clin Immunol; 2013 Dec; 13(6):623-9. PubMed ID: 24126615
[TBL] [Abstract][Full Text] [Related]
53. IgG replacement therapy, no size fits all.
Bonilla FA
Clin Immunol; 2011 May; 139(2):107-9. PubMed ID: 21420364
[No Abstract] [Full Text] [Related]
54. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies.
Dams ET; van der Meer JW
Lancet; 1995 Apr; 345(8953):864. PubMed ID: 7898254
[No Abstract] [Full Text] [Related]
55. Europe immunoglobulin map.
Šedivá A; Chapel H; Gardulf A;
Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):141-3. PubMed ID: 25546797
[No Abstract] [Full Text] [Related]
56. Immunoglobulin therapy: methods of delivery.
Ballow M
J Allergy Clin Immunol; 2008 Nov; 122(5):1038-9. PubMed ID: 18804269
[No Abstract] [Full Text] [Related]
57. Importance of ancillary supplies for subcutaneous immunoglobulin infusion: management of the local infusion site.
Duff C; Ochoa D; Riley P; Murphy E; Zampelli A
J Infus Nurs; 2013; 36(6):384-90. PubMed ID: 24202117
[TBL] [Abstract][Full Text] [Related]
58. [The use of human immunoglobulins--adverse reactions].
Pituch-Noworolska A; Błaut-Szlósarczyk A; Zwonarz K
Pol Merkur Lekarski; 2010 Sep; 29(171):202-5. PubMed ID: 20931833
[TBL] [Abstract][Full Text] [Related]
59. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].
Pac M
Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550
[TBL] [Abstract][Full Text] [Related]
60. Immune globulin subcutaneous (human) 20%: in primary immunodeficiency disorders.
McCormack PL
Drugs; 2012 May; 72(8):1087-97. PubMed ID: 22621695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
